Monogenic Diabetes

Precision Medicine Enhances Management but Not Complications in Young-Onset Diabetes: Insights from the PRISM Randomized Trial

The PRISM trial evaluated a precision medicine program using biogenetic markers and multidisciplinary care in Chinese young-onset diabetes patients, improving metabolic control and patient well-being but not reducing complications over thre